Highlights
ASX: PTX       PRESCIENT THERAPEUTICS LIMITED
Last Price Today's Change   Day's Range   Trading Volume
0.044   -0.001 (2.22%)  0.043 - 0.051  3,744,665

Overview

 
Avg Volume (4 weeks):2,155,964
4 Weeks Range:0.043 - 0.064
4 Weeks Price Volatility (%):
4.76%
52 Weeks Range:0.037 - 0.10
52 Weeks Price Volatility (%):
11.11%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company is engaged in the preparation for and conduct of clinical trials relating to the companies drugs; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. The Company is engaged in developing compounds to treat a range of solid and hematological cancers. It is pursuing the clinical and commercial development of two cancer compounds: PTX-200 and PTX-100. PTX-200 inhibits a tumor survival pathway, which plays a key role in the development of cancers. PTX-100 is a drug that kills cancer cells by blocking geranylgeranyl ransferase-1 (GGT-1). PTX-200 is in Phase Ib/IIa trials in breast and ovarian cancers, and focuses on an accruing patient for leukemia trials. PTX-100 is in Phase I of its clinical trials for breast cancer and multiple Myeloma.

  Be the first to like this.
 


 

568  561  815  2415 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 IMU 0.045+0.003 
 NHL 0.075+0.012 
 FFG 0.013+0.003 
 AUZ 0.017+0.002 
 BD1 0.032-0.003 
 TLS 3.60+0.02 
 ECT 0.0010.00 
 MLX 0.18-0.025 
 ADN 0.051+0.006 
 AVH 0.585-0.005 
Partners & Brokers